Novartis Rhapsido FDA approval adds the first targeted treatment for symptomatic dermographism, addressing persistent symptoms despite H1 antihistamines.
Granules’ 2,000 crore capex milestone strengthens its peptide CDMO push while accelerating complex generics, oncology, and higher-value pharmaceuticals.
AI is reshaping the full pharma stack, accelerating drug discovery while improving formulation, clinical testing, and delivery.
Industry experts and technology specialists explore drug development, regulatory readiness, food processing, rheology and product characterisation at Day One in Navi Mumbai
India’s TB fight gets an AI layer as Khushi Avatar joins JOSH Teams, combining digital support with youth-led community mobilisation.
AI clinical trials in India could lower drug-development costs, but CDSCO's framework must evolve as virtual trial simulations gain traction.
Anupam Rasayan moves beyond agrochemicals into branded pharma CDMO after acquiring Bliss GVS Pharma for Rs 1,750 crore.
Paediatric GLP-1 drugs in India face closer scrutiny after WHO prioritised lifestyle interventions and called for stronger evidence before wider use in children.
Neuberg and NM Medical’s merger strengthens Maharashtra’s preventive healthcare network, combining advanced diagnostics, imaging and wellness services with a Rs 500 crore revenue target.
Complex injectables in Indian pharma are gaining importance as companies invest in specialised R&D, complex formulations, and higher-value drug development.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
